{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:34:52Z","timestamp":1793932492911,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010252","name":"\u015al\u0105ski Uniwersytet Medyczny w Katowicach","doi-asserted-by":"publisher","award":["BNW-1-180\/K\/4\/K"],"award-info":[{"award-number":["BNW-1-180\/K\/4\/K"]}],"id":[{"id":"10.13039\/501100010252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010252","name":"\u015al\u0105ski Uniwersytet Medyczny w Katowicach","doi-asserted-by":"publisher","award":["BNW-1-124\/N\/3\/K"],"award-info":[{"award-number":["BNW-1-124\/N\/3\/K"]}],"id":[{"id":"10.13039\/501100010252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.seizure.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:14:24Z","timestamp":1754522064000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Antiseizure medications in CDKL5 encephalopathy\u2013 systematic review"],"prefix":"10.1016","volume":"131","author":[{"given":"Adrianna","family":"Kalinowska-Doman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-8546","authenticated-orcid":false,"given":"Justyna","family":"Paprocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.seizure.2025.08.002_bib0001","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-022-00921-5","article-title":"CDKL5 Deficiency disorder-related epilepsy: a review of current and emerging treatment","volume":"36","author":"Hong","year":"2022","journal-title":"CNS. Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pediatric16010002","article-title":"Current overview of CDKL-5 deficiency disorder treatment","volume":"16","author":"Dell'Isola","year":"2024","journal-title":"Pediatr. Rep."},{"key":"10.1016\/j.seizure.2025.08.002_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","article-title":"Cyclin-dependent Kinase-like 5 deficiency disorder: clinical review","volume":"97","author":"Olson","year":"2019","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.seizure.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.braindev.2020.12.006","article-title":"Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants","volume":"43","author":"Kobayashi","year":"2021","journal-title":"Brain Dev."},{"issue":"6","key":"10.1016\/j.seizure.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","article-title":"CDKL5 deficiency disorder: clinical features, diagnosis, and management","volume":"21","author":"Leonard","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.874695","article-title":"International consensus recommendations for the assessment and management of individuals with CDKL5 deficiency disorder","volume":"13","author":"Amin","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0007","series-title":"GeneReviews\u00ae [Internet]","first-page":"1993","article-title":"CDKL5 Deficiency disorder","author":"Benke","year":"2024"},{"key":"10.1016\/j.seizure.2025.08.002_bib0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2011.11.007","article-title":"Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations","volume":"46","author":"Moseley","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eplepsyres.2018.02.003","article-title":"Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy","volume":"141","author":"Ko","year":"2018","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.seizure.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.17826","article-title":"Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: two-year open-label extension follow-up","volume":"65","author":"Olson","year":"2024","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2025.08.002_bib0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1684\/epd.2019.1071","article-title":"Clinical evolution and epilepsy outcome in three patients with CDKL5-related developmental encephalopathy","volume":"21","author":"Bernardo","year":"2019","journal-title":"Epileptic. Disord."},{"key":"10.1016\/j.seizure.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejpn.2015.09.001","article-title":"Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy","volume":"20","author":"Mueller","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0013","doi-asserted-by":"crossref","unstructured":"CNS Drugs. 2022 Oct;36(10):1079\u2013111. doi: 10.1007\/s40263-022-00955-9.","DOI":"10.1007\/s40263-022-00955-9"},{"key":"10.1016\/j.seizure.2025.08.002_bib0014","first-page":"130","article-title":"Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients","volume":"21","author":"Amin","year":"2017","journal-title":"Hippokratia"},{"issue":"1","key":"10.1016\/j.seizure.2025.08.002_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11689-021-09384-z","article-title":"Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder","volume":"13","author":"Olson","year":"2021","journal-title":"J. Neurodev. Disord."},{"issue":"3","key":"10.1016\/j.seizure.2025.08.002_bib0016","first-page":"130","article-title":"Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients","volume":"21","author":"Amin","year":"2017","journal-title":"Hippokratia"},{"key":"10.1016\/j.seizure.2025.08.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107946","article-title":"Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: findings from a multicenter cohort","volume":"118","author":"Aledo-Serrano","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.seizure.2025.08.002_bib0018","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex."},{"key":"10.1016\/j.seizure.2025.08.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109173","article-title":"Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)","volume":"142","author":"Demarest","year":"2023","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.seizure.2025.08.002_bib0020","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.16923","article-title":"Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder","volume":"62","author":"Devinsky","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.08.002_bib0021","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla."},{"issue":"1","key":"10.1016\/j.seizure.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s13023-022-02492-6","article-title":"Efficacy of ketogenic diet in CDKL5-related epilepsy: a single arm meta-analysis","volume":"17","author":"Zhang","year":"2022","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.seizure.2025.08.002_bib0023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/gtmb.2017.0110","article-title":"Two novel variants affecting CDKL5 transcript associated with epileptic encephalopathy","volume":"21","author":"Neupauerov\u00e1","year":"2017","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.seizure.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13813","article-title":"Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: experience of >100 patients","volume":"58","author":"Lim","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.08.002_bib0025","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fneur.2018.00530","article-title":"The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy","volume":"9","author":"Ko","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpn.2021.04.007","article-title":"CDKL5 deficiency disorder in males: five new variants and review of the literature","volume":"33","author":"Siri","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.seizure.2025.08.002_bib0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eplepsyres.2018.07.013","article-title":"Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder","volume":"146","author":"Lim","year":"2018","journal-title":"Epilepsy Res."},{"issue":"17","key":"10.1016\/j.seizure.2025.08.002_bib0028","doi-asserted-by":"crossref","first-page":"9709","DOI":"10.1093\/cercor\/bhad235","article-title":"CDKL5 deficiency disorder: progressive brain atrophy may be part of the syndrome","volume":"33","author":"Specchio","year":"2023","journal-title":"Cereb. Cortex."},{"issue":"71","key":"10.1016\/j.seizure.2025.08.002_bib0029","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125001967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125001967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:40:58Z","timestamp":1788244858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"alternative-id":["S1059131125001967"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.08.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiseizure medications in CDKL5 encephalopathy\u2013 systematic review","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}